Ajanta Pharma Share Price
Ajanta Pharma Share Price Today
As of 25 Jul 2026, Ajanta Pharma share price is ₹3,369.50. The stock opened at ₹3,433.00, compared to its previous close of ₹3,439.90. During today's trading session, Ajanta Pharma share price moved in the range of ₹3,358.50 to ₹3,455.80, with an average price of ₹3,407.15 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,329.90 and a high of ₹3,598.80. On the performance front, Ajanta Pharma share price has increased by 24.81% over the last six months and is up 20.49% on a year-on-year basis.
Ajanta Pharma Returns Calculator
Ajanta Pharma Shareholder Returns
Ajanta Pharma Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,68,842.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,93,860.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,92,687.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,12,593.00 | 33.55 | 3.27 | 11.27% | 0.00 | 14.95% | 423.36 | 0.93% | 0.44 | 43.52 |
| Zydus Lifesciences | 1,11,082.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,09,553.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,05,607.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 97,364.90 | 30.58 | 2.56 | 11.07% | 0.18 | 12.54% | 377.96 | 0.69% | 0.41 | 38.68 |
| Aurobindo Pharma | 88,508.40 | 25.27 | 2.34 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,727.30 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Ajanta Pharma Financials
Income Statement · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹5,452.86 | ₹4,648.10 | ₹4,208.71 | ₹3,742.64 |
| Other Income | ₹172.07 | ₹94.50 | ₹84.60 | ₹98.64 |
| Total Revenue | ₹5,624.93 | ₹4,742.60 | ₹4,293.31 | ₹3,841.28 |
| Total Expenses | ₹4,247.28 | ₹3,553.44 | ₹3,179.38 | ₹3,096.03 |
| Profit Before Tax | ₹1,377.65 | ₹1,189.16 | ₹1,113.93 | ₹745.25 |
| Tax | ₹321.65 | ₹268.77 | ₹297.76 | ₹157.27 |
| Profit After Tax | ₹1,056.00 | ₹920.39 | ₹816.17 | ₹587.98 |
| EPS - Basic | ₹84.53 | ₹73.56 | ₹64.82 | ₹45.89 |
| EPS - Diluted | ₹84.51 | ₹73.53 | ₹64.77 | ₹45.89 |
Cash Flow · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹1,377.65 | ₹1,189.16 | ₹1,113.93 | ₹745.25 |
| Income before WC changes | ₹1,541.11 | ₹1,301.27 | ₹1,196.96 | ₹876.55 |
| Change in Assets | -₹780.61 | ₹31.26 | -₹230.57 | -₹3.45 |
| Change in Liabilities | ₹127.68 | ₹147.67 | ₹130.81 | ₹70.30 |
| Change in WC | -₹652.93 | ₹178.93 | -₹99.76 | ₹66.85 |
| Cash flow from Operations | ₹529.19 | ₹1,157.23 | ₹785.07 | ₹792.11 |
| Cash flow from Investing | -₹428.92 | -₹376.52 | ₹65.39 | -₹559.60 |
| Cash flow from Financing | -₹167.92 | -₹733.41 | -₹1,051.06 | -₹108.20 |
| Total Cash Flow | -₹67.65 | ₹47.30 | -₹200.60 | ₹124.31 |
| Cash (Start of the year) | ₹175.12 | ₹129.49 | ₹329.83 | ₹206.36 |
| Cash (End of the year) | ₹107.47 | ₹176.79 | ₹129.23 | ₹330.67 |
Balance Sheet · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹2,419.41 | ₹2,171.92 | ₹1,907.47 | ₹1,845.02 |
| Current Assets | ₹3,735.43 | ₹2,843.03 | ₹2,730.92 | ₹2,834.00 |
| Total Assets | ₹6,154.84 | ₹5,014.95 | ₹4,638.39 | ₹4,679.02 |
| Current Liabilities | ₹1,415.75 | ₹996.10 | ₹895.76 | ₹1,139.28 |
| Net Current Asset | ₹2,319.68 | ₹1,846.93 | ₹1,835.16 | ₹1,694.72 |
| Non-Current Liabilities | ₹212.00 | ₹228.56 | ₹175.27 | ₹151.75 |
| Equity Capital | ₹4,527.09 | ₹3,790.29 | ₹3,567.36 | ₹3,387.99 |
| Total Equity & Liabilities | ₹6,154.84 | ₹5,014.95 | ₹4,638.39 | ₹4,679.02 |
Income Statement · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹4,845.92 | ₹4,322.04 | ₹3,971.12 | ₹3,411.27 |
| Other Income | ₹204.40 | ₹119.87 | ₹116.48 | ₹132.75 |
| Total Revenue | ₹5,050.32 | ₹4,441.91 | ₹4,087.60 | ₹3,544.02 |
| Total Expenses | ₹3,819.29 | ₹3,261.85 | ₹2,990.65 | ₹2,844.17 |
| Profit Before Tax | ₹1,231.03 | ₹1,180.06 | ₹1,096.95 | ₹699.85 |
| Tax | ₹284.21 | ₹263.17 | ₹289.71 | ₹141.13 |
| Profit After Tax | ₹946.82 | ₹916.89 | ₹807.24 | ₹558.72 |
| EPS - Basic | ₹75.79 | ₹73.28 | ₹64.11 | ₹43.61 |
| EPS - Diluted | ₹75.78 | ₹73.25 | ₹64.06 | ₹43.61 |
Cash Flow · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹1,231.03 | ₹1,180.06 | ₹1,096.95 | ₹699.85 |
| Income before WC changes | ₹1,340.16 | ₹1,249.44 | ₹1,146.26 | ₹779.19 |
| Change in Assets | -₹319.20 | -₹42.65 | -₹261.95 | ₹43.80 |
| Change in Liabilities | ₹75.93 | ₹128.84 | ₹103.32 | ₹38.86 |
| Change in WC | -₹243.27 | ₹86.19 | -₹158.63 | ₹82.66 |
| Cash flow from Operations | ₹803.83 | ₹1,053.80 | ₹735.35 | ₹736.29 |
| Cash flow from Investing | -₹399.56 | -₹349.60 | ₹105.02 | -₹501.31 |
| Cash flow from Financing | -₹359.62 | -₹715.71 | -₹1,047.70 | -₹105.12 |
| Total Cash Flow | ₹44.65 | -₹11.51 | -₹207.33 | ₹129.86 |
| Cash (Start of the year) | ₹48.60 | ₹61.78 | ₹268.85 | ₹139.83 |
| Cash (End of the year) | ₹93.25 | ₹50.27 | ₹61.52 | ₹269.69 |
Balance Sheet · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹2,198.06 | ₹1,978.19 | ₹1,775.77 | ₹1,753.60 |
| Current Assets | ₹3,118.66 | ₹2,576.06 | ₹2,441.67 | ₹2,551.19 |
| Total Assets | ₹5,316.72 | ₹4,554.25 | ₹4,217.44 | ₹4,304.79 |
| Current Liabilities | ₹891.03 | ₹710.72 | ₹629.70 | ₹907.84 |
| Net Current Asset | ₹2,227.63 | ₹1,865.34 | ₹1,811.97 | ₹1,643.35 |
| Non-Current Liabilities | ₹202.16 | ₹218.22 | ₹174.17 | ₹150.50 |
| Equity Capital | ₹4,223.53 | ₹3,625.31 | ₹3,413.57 | ₹3,246.45 |
| Total Equity & Liabilities | ₹5,316.72 | ₹4,554.25 | ₹4,217.44 | ₹4,304.79 |
About Ajanta Pharma
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Ajanta Pharma Financial Highlights
- Revenue: Ajanta Pharma reported revenue of ₹5,624.93 crore in FY26 vs ₹4,742.60 crore in FY25. It showed an increase of 18.60% on a yearly basis.
- Operating Profit: Ajanta Pharma reported an operating profit of ₹1,377.65 crore in FY26 vs ₹1,189.16 crore in FY25. It showed an increase of 15.85% on a year-on-year basis.
- Net Profit: Ajanta Pharma reported a net profit of ₹1,056.00 crore in FY26 vs ₹920.39 crore in FY25. It showed an increase of 14.73% on a yearly basis.
Ajanta Pharma Quarterly Result Highlights
- Ajanta Pharma reported revenue of ₹1,483.07 crore in Mar 2026, compared with ₹1,399.81 crore in Dec 2025, representing an increase of 5.95% on a quarter-on-quarter (QoQ) basis.
- Ajanta Pharma reported an operating profit of ₹347.11 crore in Mar 2026, compared with ₹358.60 crore in Dec 2025, representing a decrease of 3.20% on a quarter-on-quarter (QoQ) basis.
- Ajanta Pharma reported a profit of ₹266.70 crore in Mar 2026, compared with ₹273.77 crore in Dec 2025, reflecting a decrease of 2.58% on a QoQ basis.
- The earnings per share (EPS) of Ajanta Pharma stood at ₹84.53 during Mar 2026.
Similar Stocks
FAQs on Ajanta Pharma Share Price
What is Ajanta Pharma share price today?
Ajanta Pharma share price is ₹3,369.50 as on 24 Jul, 2026, 15:50 IST.
How has the Ajanta Pharma share price performed in the past?
In the last 1 year, Ajanta Pharma delivered a return of 20.49%. The Ajanta Pharma share price hit a high of ₹3,598.80 and low of ₹2,329.90.
How much is the Mutual Fund shareholding in Ajanta Pharma shares?
The Mutual Fund Shareholding in Ajanta Pharma was 18.10% at the end of Jun 2026.
What is the the 52-week high and low of Ajanta Pharma shares ?
The 52-week high and low of Ajanta Pharma share is ₹3,598.80 and ₹2,329.90 as of 24 Jul, 2026.
What is the market cap of Ajanta Pharma?
The market capitalisation of Ajanta Pharma is ₹42,989.10 Crores as on 24 Jul, 2026.
What are the stock symbols of Ajanta Pharma?
The stock symbol of Ajanta Pharma is AJANTPHARM on the NSE, 532331 on the BSE, and the ISIN is INE031B01049.
What was yesterday's closing price of Ajanta Pharma shares ?
Ajanta Pharma shares closed yesterday at ₹3,439.90 on NSE & ₹3,440.90 on BSE
How to buy Ajanta Pharma shares?
To buy Ajanta Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Ajanta Pharma shares on Holidays?
No, shares of Ajanta Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Ajanta Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Ajanta Pharma?
The PE and PB ratio of Ajanta Pharma is 33.28 and 7.76 respectively, as on 24 Jul, 2026, 15:50 IST.


